GlassScriptPhysician profile
Lauren E Bowman
NPI 1083102057
$5,255.01
in general payments reported to CMS, 2019-2025
32 companies · $3,464 in 2025
The $3,464 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.73 · 2022: $101 · 2023: $730 · 2024: $921 · 2025: $3,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,000 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,000.13 |
| Education | $115.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,077.65 | 2024-2025 | |
| Janssen Biotech, INC. | $644.58 | 2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $369.43 | 2022-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $320.56 | 2023-2024 | Xarelto |
| Madrigal Pharmaceuticals | $316.36 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $265.46 | 2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $250.56 | 2025 | Entyvio, Eohilia |
| E.R. Squibb & Sons, L.L.C. | $197.33 | 2022-2023 | Eliquis, Camzyos |
| Lilly USA, LLC | $194.63 | 2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $184.91 | 2025 | Iqirvo |
| Pfizer INC. | $180.90 | 2023-2025 | |
| Amgen INC. | $167.89 | 2025 | Uplizna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.06 | 2023-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $133.90 | 2023-2025 | Ultomiris |
| Gilead Sciences, INC. | $129.36 | 2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $117.35 | 2025 | Tremfya |
| Celltrion USA INC. | $86.92 | 2025 | Vegzelma |
| Vifor Pharma, INC. | $63.63 | 2023 | Veltassa |
| Alnylam Pharmaceuticals INC. | $51.44 | 2025 | Givlaari |
| Novartis Pharmaceuticals Corporation | $49.36 | 2023 | |
| Genzyme Corporation | $40.15 | 2025 | |
| Shionogi INC | $38.63 | 2023 | Fetroja |
| Ferring Pharmaceuticals INC. | $29.45 | 2024 | Rebyota |
| Insmed, INC. | $26.91 | 2023 | Arikayce |
| Paratek Pharmaceuticals, INC. | $24.99 | 2024 | Nuzyra |
| Astrazeneca Pharmaceuticals LP | $24.51 | 2022 | |
| Astellas Pharma US INC | $21.11 | 2021 | |
| Phathom Pharmaceuticals, INC. | $20.40 | 2025 | Voquezna |
| Novo Nordisk INC | $19.65 | 2025 | Wegovy |
| Vivus LLC | $19.11 | 2025 | Pancreaze |
| Csl Behring | $17.62 | 2021 | |
| Merck Sharp & Dohme LLC | $16.20 | 2024 | Dificid, Zerbaxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Bowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.